The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase () inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI showed limited response, with only 11% of patients having objective responses. Studies suggest that serial PET imaging with radiolabeled amino acids, such as -(2-[ F]-fluoroethyl)-L-tyrosine (FET) PET, may provide earlier and more informative assessments of treatment response than MRI. In an initial experience with FET PET, 3 out of 5 patients showed metabolic response to vorasidenib. This highlights FET PET's potential to guide decision-making, though further trials are needed to confirm outcome benefits.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683584 | PMC |
| http://dx.doi.org/10.1093/noajnl/vdae210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of early metabolic changes following vorasidenib using FET PET in patients with -mutant gliomas.
Neurooncol Adv
November 2024
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
The phase-3 INDIGO trial demonstrated that the isocitrate dehydrogenase () inhibitor vorasidenib significantly prolonged progression-free survival and delayed intervention in patients with CNS WHO grade 2 gliomas. However, conventional MRI showed limited response, with only 11% of patients having objective responses. Studies suggest that serial PET imaging with radiolabeled amino acids, such as -(2-[ F]-fluoroethyl)-L-tyrosine (FET) PET, may provide earlier and more informative assessments of treatment response than MRI.
View Article and Find Full Text PDF[A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model].
Zh Vopr Neirokhir Im N N Burdenko
December 2024
Burdenko Neurosurgical Center, Moscow, Russia.
Unlabelled: The development of new drugs in nuclear medicine for diagnosis or treatment (chemotherapy) of brain tumors, in particular gliomas, is inextricably linked with the use of tumor models in animals (usually rats).
Objective: To compare the widely used glioma cell model C6 and the new experimental tissue model of glioblastoma 101.8.
Added prognostic value of DCE blood volume imaging in patients with suspected recurrent or residual glioblastoma-A hybrid [F]FET PET/MRI study.
Neurooncol Adv
November 2024
Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Background: Magnetic resonance imaging (MRI) cerebral blood volume (CBV) measurements improve the diagnosis of recurrent gliomas. The study investigated the prognostic value of dynamic contrast-enhanced (DCE) CBV imaging in treated IDH wildtype glioblastoma when added to MRI or amino acid positron emission tomography (PET).
Methods: Hybrid [F]FET PET/MRI with 2CXM (2-compartment exchange model) DCE from 86 adult patients with suspected recurrent or residual glioblastoma were retrospectively analyzed.
Magnetic resonance imaging and o-(2-[F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.
Neurooncol Adv
October 2024
Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
Background: In the present study, early response assessment by o-(2-[F]fluoroethyl)-l-tyrosine (FET) positron emission tomography (PET) and contrast-enhanced magnetic resonance imaging (MRI) were investigated in a phase II open-label single-center study of nivolumab plus bevacizumab for recurrent high-grade astrocytic glioma.
Methods: Twenty patients with nonresectable first recurrence of high-grade astrocytic glioma after EORTC/NCIC protocol underwent [F]FET PET/MRI at baseline and after 2 cycles of treatment. Whole brain values of contrast-enhancing volume on MRI (CEV), of the mean (TBR) and maximal tumor-to-background ratio (TBR), and of metabolically active volume (MTV) on [F]FET PET were obtained.
F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study.
Ann Nucl Med
November 2024
Department of Nuclear Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, 970423, Taiwan.
Article Synopsis
- The study investigated the effectiveness of fluorine-18-labeled fluoroethyltyrosine PET/CT in diagnosing brain tumors in Asian patients, comparing it to another method (F-FDG PET/CT).
- A total of 33 patients were assessed, revealing that F-FET identified a higher percentage of true cases and showed better diagnostic accuracy and sensitivity compared to F-FDG.
- Key results indicated F-FET PET/CT had a sensitivity of 96.2% and accuracy of 93.9%, suggesting it might be a superior tool for detecting brain tumors and assessing glioma recurrence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!